Knight Therapeutics First Quarter 2025 Earnings: Beats Expectations

Knight Therapeutics (TSE:GUD) First Quarter 2025 Results

Key Financial Results

• Revenue: CA$88.1m (up 1.7% from 1Q 2024).
• Net income: CA$2.19m (up from CA$4.55m loss in 1Q 2024).
• Profit margin: 2.5% (up from net loss in 1Q 2024).
• EPS: CA$0.022 (up from CA$0.045 loss in 1Q 2024).

We've discovered 1 warning sign about Knight Therapeutics. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Knight Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 7.5% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Knight Therapeutics that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.